Stockscreener 앱 받기
15.49
1.27%
0.195
시간 외 거래:
15.49
전일 마감가:
$15.29
열려 있는:
$14.96
하루 거래량:
586.25K
Relative Volume:
0.98
시가총액:
$897.91M
수익:
$1.23M
순이익/손실:
$-214.90M
주가수익비율:
-3.7577
EPS:
-4.1222
순현금흐름:
$-151.25M
1주 성능:
-8.99%
1개월 성능:
-21.37%
6개월 성능:
-44.04%
1년 성능:
-54.85%
1일 변동 폭
$14.90
$15.80
1주일 범위
$14.90
$18.27
52주 변동 폭
$14.90
$40.84
Spyre Therapeutics Inc Stock (SYRE) Company Profile
명칭
Spyre Therapeutics Inc
전화
(617) 651-5940
주소
221 CRESCENT STREET, WALTHAM
SYRE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SYRE
Spyre Therapeutics Inc
|
15.49 | 897.91M | 1.23M | -214.90M | -151.25M | -4.1222 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.49 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
625.60 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
583.62 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.83 | 34.53B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
274.78 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Spyre Therapeutics Inc Stock (SYRE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-18 | 개시 | Wolfe Research | Outperform |
| 2024-09-04 | 개시 | Wedbush | Outperform |
| 2024-07-16 | 개시 | Evercore ISI | Outperform |
| 2024-05-02 | 개시 | Robert W. Baird | Outperform |
| 2024-03-01 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-12-20 | 개시 | BTIG Research | Buy |
| 2023-12-11 | 개시 | Guggenheim | Buy |
| 2023-12-11 | 개시 | Jefferies | Buy |
| 2020-05-04 | 개시 | Piper Sandler | Overweight |
| 2019-03-21 | 개시 | JP Morgan | Overweight |
| 2018-09-04 | 다운그레이드 | Wells Fargo | Outperform → Market Perform |
| 2018-04-24 | 개시 | Evercore ISI | Outperform |
| 2018-03-14 | 재확인 | Needham | Buy |
모두보기
Spyre Therapeutics Inc 주식(SYRE)의 최신 뉴스
Teacher Retirement System of Texas Takes Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Spyre Therapeutics (NASDAQ:SYRE) Shares Gap Up – What’s Next? - Defense World
Swiss National Bank Buys 19,000 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Spyre Therapeutics Starts Dosing in Phase 1 Trial for IL-23 Antibody SPY003 - Marketscreener.com
Game-Changing IL-23 Antibody Enters Clinical Trials: Quarterly Dosing Could Transform Treatment - Stock Titan
Head to Head Contrast: Spyre Therapeutics (NASDAQ:SYRE) & Aptorum Group (NASDAQ:APM) - Defense World
Charles Schwab Investment Management Inc. Has $8.84 Million Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Bank of New York Mellon Corp Decreases Stock Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Will Spyre Therapeutics Redefine IBD Treatment With Superior Efficacy And Convenience? - RTTNews
Spyre Therapeutics (NASDAQ:SYRE) Coverage Initiated by Analysts at Wolfe Research - Defense World
Wolfe Research Initiates Spyre Therapeutics at Outperform With $27 Price Target -March 18, 2025 at 07:17 am EDT - Marketscreener.com
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Shares Acquired by Arizona State Retirement System - Defense World
Victory Capital Management Inc. Takes Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Spyre Therapeutics Announces Grants of Inducement Awards - cnhinews.com
Spyre Therapeutics Inc (SYRE) Announces Stock Option Grants to Non-Executive Employees - GuruFocus.com
132,200 New Stock Options: Inside Spyre Therapeutics' Latest Employee Compensation Package - StockTitan
Rhumbline Advisers Boosts Holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Spyre Therapeutics Faces Compliance Hurdles After Transition from Smaller Reporting Company Status - MSN
Spyre Therapeutics Inc (SYRE) deserves closer scrutiny - US Post News
Spyre Therapeutics: Targeting The Future Of IBD Treatment - Seeking Alpha
Spyre Therapeutics (NASDAQ:SYRE) Trading 6.6% Higher After Strong Earnings - Defense World
Spyre Therapeutics (NASDAQ:SYRE) Posts Earnings Results, Beats Expectations By $0.08 EPS - MarketBeat
Buy Rating for Spyre Therapeutics Driven by Promising Drug Development and Strong Financial Position - TipRanks
Spyre Therapeutics: Q4 Earnings Snapshot - The Pioneer
Decoding Spyre Therapeutics Inc (SYRE): A Strategic SWOT Insight - GuruFocus.com
Spyre Therapeutics Reports Strong Progress and Financial Stability - TipRanks
Spyre Therapeutics reports Q4 EPS (81c), consensus (94c) - TipRanks
Spyre Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Spyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - PR Newswire
Spyre Therapeutics (SYRE) Projected to Post Earnings on Thursday - Defense World
Recent Insider Activity Could Benefit Spyre Therapeutics Inc (SYRE) - Knox Daily
SYRE Stock Touches 52-Week Low at $20.24 Amid Market Challenges - Investing.com Australia
Spyre Therapeutics (NASDAQ:SYRE) Hits New 1-Year LowTime to Sell? - MarketBeat
Spyre Therapeutics to Participate in Upcoming March Investor Conferences - PR Newswire
IBD-Focused Spyre Therapeutics Sets Investor Conference Schedule for MarchWhat to Expect - Stock Titan
Spyre Therapeutics (NASDAQ:SYRE) Upgraded at The Goldman Sachs Group - Defense World
Spyre Therapeutics, Inc. (SYRE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Can This Novel Dual-Action IBD Treatment Transform Patient Care? New Data Reveals Promising Results - StockTitan
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Consensus Recommendation of “Buy” by Analysts - Defense World
1,955 Shares in Spyre Therapeutics, Inc. (NASDAQ:SYRE) Acquired by Mirae Asset Global Investments Co. Ltd. - Defense World
InvestingPro Fair Value analysis proves accurate on Spyre Therapeutics call - MSN
Can Spyre Therapeutics (SYRE) Climb 158.85% to Reach the Level Wall Street Analysts Expect? - MSN
InvestingPro Fair Value analysis proves accurate on Spyre Therapeutics call By Investing.com - Investing.com
Spyre (SYRE) Unveils Strategic Talent Retention Plan: 35K Options with 10-Year Window - StockTitan
China Universal Asset Management Co. Ltd. Makes New Investment in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - MarketBeat
Spyre Therapeutics Inc (SYRE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.00%
자본화:
|
볼륨(24시간):